Editorial’s comment to the article “Immediate Results of Preoperative Chemo-targeting Therapy in Patients with Rectal Cancer” by the authors: Aleksey Yu. Dobrodeev, Anna S. Tarasova, Sergey G. Afanasyev, Dmitry N. Kostromitsky, Anastasia A. Ponomareva, Natalia N. Babyshkina, Tatyana A. Dronova, Irina V. Larionova, Natalia V. Yunusova

1. Fedyanin M.Yu., Gladkov O.A., Gordeev S.S., et al. Cancer of the colon, rectosigmoid junction and rectum. RUSSCO prectical recommendation, part 1.1. Malignant tumors. 2024;14(3s2):263–322. (In Russ.).

2. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetux-imab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–1627.

3. Liu C, Zhong C, Liu H, et al. Modified FOLFOX6 with Cetuximab versus with Radiotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Single-Center, Prospective, Randomized Controlled Trial. Biol Pharm Bull. 2024;47(10):1675–1681.

4. Velenik V, Ocvirk J, Oblak I, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. J Eur Soc Surg Oncol. 2010;36(3):244–250.